Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Asset Writedowns and Impairment (2017 - 2023)

Historic Asset Writedowns and Impairment for Amicus Therapeutics (FOLD) over the last 8 years, with Q4 2023 value amounting to $367000.0.

  • Amicus Therapeutics' Asset Writedowns and Impairment fell 5949.23% to $367000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $1.5 million, marking a year-over-year decrease of 8004.52%. This contributed to the annual value of $9.2 million for FY2024, which is 23773.38% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Asset Writedowns and Impairment of $367000.0 as of Q4 2023, which was down 5949.23% from $1.1 million recorded in Q2 2023.
  • Over the past 5 years, Amicus Therapeutics' Asset Writedowns and Impairment peaked at $6.6 million during Q1 2022, and registered a low of $367000.0 during Q4 2023.